Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.69 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.69 |
| ▸ | CXCR1 | P25024 | 12/20 | 0.64 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19600983 | 0.95 | CXCR1 (0.73) | CYP1A2CYP19A1CYP2C9CYP2C19CXCR1 | |
| SCHEMBL17951705 | 0.95 | CYP1A2 (0.67) | CYP1A2CYP19A1CYP2C9CYP2C19CXCR1 | |
| SCHEMBL7339631 | 0.95 | CYP1A2 (0.63) | CYP1A2CYP19A1CYP2C9CYP2C19CXCR1 | |
| SCHEMBL17822356 | 0.92 | CYP1A2 (0.60) | CYP1A2CYP19A1CYP2C9CYP2C19CXCR1 | |
| SCHEMBL10929143 | 0.92 | CXCR1 (0.66) | CYP1A2CYP19A1CYP2C9CYP2C19CXCR1 | |
| SCHEMBL18314374 | 0.92 | CYP1A2 (0.70) | CYP1A2CYP19A1CYP2C9CYP2C19CXCR1 | |
| SCHEMBL8379934 | 0.91 | CYP1A2 (0.59) | CYP1A2CYP19A1CYP2C9CYP2C19CXCR1 | |
| SCHEMBL16557179 | 0.91 | CYP1A2 (0.59) | CYP1A2CYP19A1CYP2C9CYP2C19CXCR1 | |
| SCHEMBL677562 | 0.91 | CYP1A2 (0.59) | CYP1A2CYP19A1CYP2C9CYP2C19CXCR1 | |
| SCHEMBL6538529 | 0.91 | CYP1A2 (0.59) | CYP1A2CYP19A1CYP2C9CYP2C19CXCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4784093-B2 | — | — | 2011-09-28 | — | — | JP | claimed |
| US-20050227914-A1 | New process | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-10-13 | — | — | US | claimed |
| WO-2004014879-A1 | NEW PROCESS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-02-19 | — | — | WO | claimed |
| US-7199248-B2 | Process | ASTELLAS PHARMA INC. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20050227914-A1 | New process | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-10-13 | — | — | US | disclosed |
| WO-2004014879-A1 | NEW PROCESS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227914-A1 | New process | CA2, AKR1C3, AGTR2 | CYP1A2 5/4885CYP19A1 171/4885CYP2C9 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.